A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer
Conditions
- Metastatic Colorectal Cancer (CRC)
- mCRC
Interventions
- DRUG: Iparomlimab and Tuvonralimab (QL1706)
- DRUG: Fruquintinib
- RADIATION: Heterogeneous Radiotherapy
Sponsor
Huazhong University of Science and Technology
Collaborators